5 ms·

> It's a pretty tough call. It’s actually not a tough call. It just reveals how broken the system is. There should be a way for drugs to be experimentally app

by tomp 5y ago

> It's a pretty tough call. It’s actually not a tough call. It just reveals how broken the system is. There should be a way for drugs to be experimentally approved, where patients can only take them with extra consent / oversight (e.g. recommended by an ethics committee, or after a 6 month waiting period & clear understanding of side effects), specifically for cases where the potential benefits outweigh possible risks. Alzheimer’s sounds like a good candidate, or near-fatal diseases (6-month-to-live cancer) - you literally have nothing to lose! Another example is a pandemic, where the vaccine was experimentally approved, but presumably only because of the enormous scale & economic benefits (but the individual benefits are equivalent, or even greater, in the cases above).

hulitu 5y ago
> There should be a way for drugs to be experimentally approved, where patients can only take them with extra consent / oversight (e.g. recommended by an ethics committee, or after a 6 month waiting period & clear understanding of side effects), specifically for cases where the potential benefits outweigh possible risks. There is. See how EMA approved Covid-19 vaccines.
- j_wtf_all_taken 5y ago
  That, and with respect to: > Alzheimer’s sounds like a good candidate, or near-fatal diseases (6-month-to-live cancer) - you literally have nothing to lose! But others have a lot to lose. No matter how experimental the application and how much consent and oversight - if the drug is being used on people before finishing all testing and without taking all necessary precautions, you increase the risk of side or adverse effects. That in turn will likely delay the approval of the drug for all patients. So in the end, a couple of people get experimental treatment but might delay the treatment for a large group of people. That's no easy trade-off, and is certainly not a sign for a broken system.
  - HPsquared 5y ago
    As I understand it, safety testing has already been done but it's apparently more difficult to test the efficacy.

by tomp 5y ago

hulitu 5y ago

> There should be a way for drugs to be experimentally approved, where patients can only take them with extra consent / oversight (e.g. recommended by an ethics committee, or after a 6 month waiting period & clear understanding of side effects), specifically for cases where the potential benefits outweigh possible risks. There is. See how EMA approved Covid-19 vaccines.

j_wtf_all_taken 5y ago
That, and with respect to: > Alzheimer’s sounds like a good candidate, or near-fatal diseases (6-month-to-live cancer) - you literally have nothing to lose! But others have a lot to lose. No matter how experimental the application and how much consent and oversight - if the drug is being used on people before finishing all testing and without taking all necessary precautions, you increase the risk of side or adverse effects. That in turn will likely delay the approval of the drug for all patients. So in the end, a couple of people get experimental treatment but might delay the treatment for a large group of people. That's no easy trade-off, and is certainly not a sign for a broken system.
- HPsquared 5y ago
  As I understand it, safety testing has already been done but it's apparently more difficult to test the efficacy.